RA Treatment: When Biologic Fails MedPage Today The most commonly used non-TNF agents in RA are rituximab (Rituxan), a B-cell-depleting monoclonal antibody, abatacept (Orencia), a selective T-cell costimulation modulator, and tocilizumab (Actemra), a monoclonal antibody targeting the interleukin-6 ... |
